Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Alanine aminotransferase normal, Arthralgia, Aspartate aminotransferase, Bilirubin conjugated, Biopsy
Clinical narrative: The hip pain had made it difficult to impossible for him to walk; hip pain; mild to moderate annoying discomfort; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient.  A 77 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in deltoid right, administration date 04Apr2021 10:15 (Lot number: ER8729) at the age of 77 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Prostate Cancer metastatic castration sensitive", start date: 05May2019 (ongoing), notes: 1 biopsy and PEJ scan only diagnosed after B.O.B and renal obstruction.; "renal obstruction" (unspecified if ongoing); "Arthritis low back", start date: 21Jan2017 (ongoing), notes: old age sequel of 50 years age acute injury; "acute injury" (unspecified if ongoing); "MI", start date: 1995, stop date: 1996, notes: right coronary sclerotic insert, 1 stent placed; Dist changed; "right coronary sclerotic insert, 1 stent placed; Dist changed" (unspecified if ongoing); "Right inguinal lymph nodes removed", start date: 1967 (ongoing), notes: misdiagnosed infection; inappropriate surgery; erroneous post of anal apathy diagnosis. Family medical history included: his mother died at age of 80 in 1992, his father was killed by influenza virus, cirrhosis of liver at age 57, 1967, his grandparents all lived past age 80 (or 85) no direct off spring by him, sole sibling- age now 72 year; healthy, athletic, history of asthma (respective). Concomitant medication(s) included: ZYTIGA taken for neoplasm malignant, start date: 2019 (ongoing); XGEVA taken for neoplasm malignant, start date: 2019 (ongoing); PREDNISONE, start date: 2019 (ongoing); ELIGARD taken for neoplasm malignant, start date: 2019 (ongoing). The following information was reported: DISCOMFORT (non-serious) with onset Apr2021, outcome "unknown", described as "mild to moderate annoying discomfort"; ARTHRALGIA (non-serious) with onset Apr2021, outcome "recovering", described as "hip pain"; GAIT INABILITY (non-serious) with onset 11Apr2021, outcome "recovering", described as "The hip pain had made it difficult to impossible for him to walk". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of arthralgia, gait inability. The events were also described as mild to moderate annoying discomfort that had existed there since about 1-2 weeks after the 1st vaccination and that was not great enough to cause him to hammer his doctor about it. The hip pain had made it difficult to impossible for him to walk on 11Apr2021, and after his cancer treatment visit (given Xgiva routine cancer treatment injection then), eating 3.75 mg hydrocodone + 187 g acetaminophen once, prescribed relief for pain (lzya 7.5/325 mg hydrocodone apap) was referred 5 mg, afterward became able to walk without a crutch on 15Nov2021.  The reporting consumer considered the Pfizer product had a causal effect to the adverse event.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101529752 same patient/vaccine, different dose/events